- Home
- UTMD vs NBP Comparison
UTMD vs NBP Comparison
Compare UTMD & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UTMD | NBP |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.1M | 225.5M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UTMD | NBP |
|---|---|---|
| Price | $72.77 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 21.7K | ★ 248.1K |
| Earning Date | 04-23-2026 | 04-07-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $38,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.66 | $1.46 |
| 52 Week High | $75.75 | $5.19 |
Technical Indicators
Market Signals| Indicator | UTMD | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 50.11 |
| Support Level | $68.93 | $1.78 |
| Resistance Level | $74.75 | $1.98 |
| Average True Range (ATR) | 1.53 | 0.10 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 71.01 | 34.36 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.